
Sermo and LiveWorld survey of 50+ pharma marketers and 200+ physicians finds that social media plays a major role in influencing perceptions of medications, prescribing Habits, ongoing medical education and professional networking.

Sermo and LiveWorld survey of 50+ pharma marketers and 200+ physicians finds that social media plays a major role in influencing perceptions of medications, prescribing Habits, ongoing medical education and professional networking.

The capabilities will support life sciences organizations with a variety of use cases, including health care provider (HCP) interactions, HCP education, and patient education.

A new study shows that a growing number of younger generations are turning to social media platforms such as TikTok and Instagram influencers for health advice.

Move enables FINN to address pressing health priorities in developed and developing nations and expands Hyderus global service capabilities and client offerings and Hyderus co-founders Mark Chataway and Christopher Nial join FINN global health leaders team.

Webcasts
Webinar Date/Time: Mon, Mar 13, 2023 11:00 AM EDT

Fran Pollaro talks with Faruk Capan is the CEO, EVERSANA INTOUCH & Chief Innovation Officer, EVERSANA about the arrival of Chat GPT and generative AI in the public consciousness. This is just the beginning.

Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.

AstraZeneca is forecasting growth in 2023 and beyond, relying on its expanding line of cancer, metabolic, and rare disease drugs to offset declining COVID product sales.

Branding agency experts share what to know when it comes to legal, regulatory, and creative approaches in the complex drug-naming process, with its potential to shape a campaign’s success.

BMS launched a new direct-to-consumer (DTC) campaign for SOTYKTU™ (deucravacitinib) for the plaque psoriasis community.

U.S. Food and Drug Administration has greenlighted the use of Trodelvy for a third indication.

Sysnav Healthcare and Roche enter a partnership to facilitate development of industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav's technology.

What’s changing in post-pandemic HCP access? Veeva’s vice president of global business consulting unveils the latest data.

Q&A addresses patient care and leads to digital solutions like telehealth as a strong delivery vehicle and an opportunity for marketers.

"AH-ha!™ It's Acne Hormones" features people affected by acne and highlights "AH-ha" moments to "pop" common acne myths and misconceptions.

Launch Ready from Day One is designed to empower a company's customer facing teams to drive demand, simplify access, and create a seamless and more integrated customer experience.

New structure strengthens offerings and drives the addition of diversified marketing services.

Adding more than 100 employees to its team in 2022, the company's growth has outpaced growth in the broader healthcare advertising segment, as pharmaceutical marketers increasingly embrace digital advertising, particularly on CTV.

Indegene expands on significant presence by adding to existing UK, Ireland, and Switzerland centers.

What the c-suite should consider in today’s marketplace.

The parameters governing pharma promotional speech in digital and social media have struggled to keep pace with the rapidly evolving healthcare communications landscape. How can FDA play catch-up in advancing an agenda more reflective of industry and patient needs?

As they are forced to do more with less, pharma commercial leaders should rethink their incentive programs to ensure their sales teams remain strong drivers of growth.

"The customer is always right" — a commitment to omnichannel marketing is a commitment to serving the customer. David Laros of Beghou Consulting offers up this tersely written playbook on the topic.

The Anglo-Swedish drugmaker on Monday agreed to pay $26 per CinCor share in cash, or $1.3 billion in total, a premium of nearly 121% to the U.S.-based company's closing price on Friday.

Fran Pollaro chats with with Indegene's Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts and Jack Mycka, Vice President, Enterprise Medical Solutions and Emerging Biotech.